Tamoxifen-induced DNA adducts in leucocytes of breast cancer patients

Carcinogenesis

Volumn 18, Issue 1, 1997, Pages 9-13

  Hemminki, Kari ^a   Rajaniemi, Heli ^a   Koskinen, Mikko ^a   Hansson, Johan ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHORUS 32; TAMOXIFEN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DNA ADDUCT; DRUG DNA INTERACTION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LEUKOCYTE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, THIN LAYER; DNA ADDUCTS; DNA, NEOPLASM; FEMALE; HUMANS; LEUKOCYTES; MIDDLE AGED; RATS; TAMOXIFEN;

EID: 0031409631     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/18.1.9     Document Type: Article

References (31)

1. Jordan, V.G. (1993) How safe is tamoxifen? Br. Med. J., 307, 1371-1372.
2. Greaves, P., Goonettilleke, P., Nunn, G., Topham, J. and Orton, T. (1993) Two- year carcinogenicity study of tamoxifen in Alderley Rark Wistar-derived rats. Cancer Res., 53, 3919-3924.
3. Hard, G.C., Iantropoulos, M.J., Jordan, K., Radi, L., Kaltenberger, O.P., Imondi, A.R. and Williams, G.M. (1993) Major differences in the hepatocarcinogenicity and DNA adduct forming ability between toremofene and tamoxifen in female Crl:CD(BR) rats. Cancer Res., 53, 4534-4541.
4. Williams, G.M., Iatropoulos, M.J., Djordjevics, M.V. and Kaltenberg, O.P. (1993) The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis, 14, 315-317.
5. Hirsimäki, P., Hirsimäki, Y., Nieminen, L. and Payne, B.J. (1993) Tamoxifen induces hepatocellular carcinoma in rat liver: a 1-year study with two antiestrogens. Arch. Toxicol., 67, 49-54.
6. Han, X. and Liehr, J.G. (1992) Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res., 52, 1360-1363.
7. White, I.N.H., deMatteis, F., Davies, A., Smith, L.L., Crofton-Sleigh, C., Venitt, S., Hewer, A. and Phillips, D.H. (1992) Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells. Carcinogenesis, 13, 2197-2203.
8. Randerath, K., Bi, J., Mabon, N., Sriram, P. and Moorthy, B. (1994) Strong intensification of mouse hepatic tamoxifen DNA adduct formation by pretreatment with the sulfotransferase inhibitor and ubiquitous environmental pollutant pentachlorophenol. Carcinogenesis, 15, 797-800.
9. Osborne, M.R., Hewer, A., Harcastle, I.R., Carmichael, P.L. and Phillips, D.H. (1996) Identification of the major tamoxifen-deoxygyanosine adduct formed in the liver DNA of rats treated with tamoxifen. Cancer Res., 56, 66-71.
10. 32P-postlabeling and use of metabolic inhibitors for two distict pathways leading to mouse hepatic DNA adduct formation and identification of 4-hydroxytamoxifen as a proximate metabolite. Carcinogenesis, 15, 2087-2094.
11. Hemminki, K., Widlak, P. and Hou, S.-M. (1995) DNA adducts caused by tamoxifen and toremifene in human microsomal system and lymphocytes in vitro. Carcinogenesis, 16, 1661-1664.
12. Pongracz, K., Pathak, D.N., Nakamura, T., Burlingame, A.L. and Bodell, W.J. (1995) Activation of the tamoxifen metabolite E to form DNA adducts:comparison with the adducts formed by microsomal activation of tamoxifen. Cancer Res., 55, 3012-3015.
13. Pathak, D.N. and Bodell, W.J. (1994) DNA adduct formation by tamoxifen with rat and human liver microsomal activation systems. Carcinogenesis, 15, 529-532.
14. Rutqvist, L.-E. and Mattson, A. (1993) Cardiac and thromboembolic morbidity among postmenopausal women with early-stage cancer in a randomized trial of adjuvant tamoxifen. J. Natl Cancer Inst., 85, 1398-1406.
15. Fisher, B., Costantino, J.P., Redmond, C.K., Fisher, E.R., Wickerham, D.L. and Cronin, W.M. (1994) Endometrial cancer in tamoxifen-treated breast cancer patient:findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-12. J. Natl Cancer Inst., 86, 527-537.
16. King, C.M. (1995) Tamoxifen and the induction of cancer. Carcinogenesis, 16, 1449-1454.
17. IARC (1996) Monographs on the Evaluation of Carconogenic Risks to Humans, vol 66. Some Pharmaceutical Drugs. International Agency for Research on Cancer, Lyon.
18. 32P-Postlabelled DNA adducts in liver obtained from women treated with tamoxifen. Carcinogenesis, 16, 1651-1654.
19. Carmichael, P.L., Ugwumadu, A.H.N., Neven, P., Hewer, A.J., Poon, G.K. and Phillips, D.H. (1996) Lack of genotoxicity of tamoxifenin human endometrium. Cancer Res., 56, 1475-1479.
20. Phillips, D.H., Hewer, A., Grover, P.L., Poon, G.K. and Carmichael, P.L. (1996) Tamoxifen does not form detectable adducts in white blood cells of breast cancer patients. Carcinogenesis, 17, 1149-1152.
21. 32P-postlabelling techniques. A comparison of HPLC-and TLC-assays. J. Chromatogr., in press.
22. Hemminki, K. (1993) DNA adducts, mutations and cancer. Carcinogenesis, 14, 969-973.
23. Hemminki, K. (1995) DNA adducts in biomonitoring. J. Occup. Environ Med., 37, 44-51.
24. Hemminki, K., Rajaniemi, H., Lindahl, B. and Moberger, B. (1996) Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients. Cancer Res., 56, 4374-4377.
25. Potter, G.A., McCague, R. and Jarman, M.(1994) A mechanistic hypothesis for DNA adduct formation by tamoxifen following hepatic oxidative metabolism. Carcinogenesis, 15, 439-442.
26. 5-ethyl)tamoxifen implicates alpha-hydroxylation of the ethyl group as a major pathway of tamoxifen activation to a liver carcinogen. Carcinogenesis, 15, 1487-1492.
27. Hard, G.C., Iatropoulos, M.J., Jordan, K., Radi, L., Kaltenberg, O.P., Imondi, A.R. and Williams, G. (1993) Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats. Cancer Res., 53, 4534-4541.
28. Montandon, F. and Williams, G.M. (1994) Comparison of DNA reactivity of the polyphenylethylene hormonal agents diethylstilbestrol, tamoxifen and toremifene in rat and hamster liver. Arch. Toxicol., 86, 272-275.
29. 32P-HPLC. Carcinogenesis, 14, 1453-1459.
30. 32P-postlabeled DNA adducts. Carcinogenesis, 14, 1343-1348.
31. 32P-postlabelling assays for cisplatin-DNA adducts. Carcinogenesis, 15, 2829-2834.